International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)

(2013) Bernard Tawfik et al.   ANNALS OF HEMATOLOGY

Elacytarabine has single-agent activity in patients 
with advanced acute myeloid leukaemia

(2012) Susan O'Brien et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

(2012) F J Giles et al.   LEUKEMIA

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

(2012) Ellen K. Ritchie et al.   LEUKEMIA & LYMPHOMA

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

(2011) Auke D. Adema et al.   INVESTIGATIONAL NEW DRUGS

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY